tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2022-12-3s1-62-68tumors-1002Research ArticleСтатьиОсобенности селекции пациентов для метастаз-направленной терапии при олигометастатическом РПЖ: можно ли обойтись без системного лечения?ВолковаМ. И.

Москва

mivolkova6@gmail.comАль-АкелИ. С.

Москва

ГБУЗ «ГКОБ № 1» ДЗМ; Кафедра онкологии и паллиативной медицины им. А. И. Савицкого ФГБОУ ДПО РМАНПОRussian FederationГБУЗ «ГКОБ № 1» ДЗМRussian Federation202218112022123s16268Copyright © Волкова М.И., Аль-Акел И.С., 20222022Волкова М.И., Аль-Акел И.С.Волкова М.И., Аль-Акел И.С.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/1002

Интенсификация первой линии терапии мГЧРПЖ, диагностированного de novo, привела к значимому увеличению ОВ этой категории больных. Стандартом лечения олигометастатического рака предстательной железы являются комбинации АДТ с антиандрогенами второго поколения. Совершенствование методов диагностики привело к росту доли олигометастатического рака предстательной железы (ОМРПЖ) среди впервые выявленных больных и пациентов, ранее получавших лечение. Растет доказательная база, подтверждающая позитивную роль локального лечения первичной опухоли при диссеминированном раке простаты, однако необходимы данные рандомизированных исследований для определения показаний к циторедуктивным манипуляциям. Метастаз-направленная терапия демонстрирует многообещающие результаты, однако уровень доказательной базы низок, и локальное лечение олигометастазов пока остается экспериментальным методом лечения, требует дальнейшего изучения в статистически значимых группах.

олигометастатический рак предстательной железыолигометастазыметастаз-направленная терапиярецидив рака предстательной железыReferencesHellman S, Weichselbaum RR. Oligometastases. J ClinOncol 1995 ; 13 : 8–10. 10.1200/JCO.1995.13.1.8Hellman S, Weichselbaum RR. Oligometastases. J ClinOncol 1995 ; 13 : 8–10. 10.1200/JCO.1995.13.1.8Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev ClinOncol 2011 ; 8 : 378–82. 10.1038/nrclinonc. 2011.44.Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev ClinOncol 2011 ; 8 : 378–82. 10.1038/nrclinonc. 2011.44.Singh D., Int J RadiatOncolBiol Phys. 2004 ; 58 : 3–10.Singh D., Int J RadiatOncolBiol Phys. 2004 ; 58 : 3–10.Corbin K. S. J ClinOncol. 2013 ; 31 : 1384–1390.Corbin K. S. J ClinOncol. 2013 ; 31 : 1384–1390.Tosoian JJ, Gorin MA, Ross AE, et al. Oligometastatic prostate cancer : Definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 2017 ; 14 : 15–25.10.1038/nrurol.2016.175.Tosoian JJ, Gorin MA, Ross AE, et al. Oligometastatic prostate cancer : Definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 2017 ; 14 : 15–25.10.1038/nrurol.2016.175.Slaoui A, Albisinni S, Aoun F, et al. A systematic review of contemporary management of oligometastatic prostate cancer : fighting a challenge or tilting at windmills?World J Urol2019 ; 37 : 2343–53. 10.1007/s00345–019–02652–7.Slaoui A, Albisinni S, Aoun F, et al. A systematic review of contemporary management of oligometastatic prostate cancer : fighting a challenge or tilting at windmills?World J Urol2019 ; 37 : 2343–53. 10.1007/s00345–019–02652–7.Front. Oncol., 28 January 2022 Sec. Radiation Oncology https://doi.org/10.3389/fonc.2022.831429.Front. Oncol., 28 January 2022 Sec. Radiation Oncology https://doi.org/10.3389/fonc.2022.831429.Taneja SS. Re : Apalutamide for metastatic, castration-sensitive prostate cancer. J Urol2019 ; 202 : 661. 10.1097/01. JU. 0000577260.12278.1c.Taneja SS. Re : Apalutamide for metastatic, castration-sensitive prostate cancer. J Urol2019 ; 202 : 661. 10.1097/01. JU. 0000577260.12278.1c.Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer : long-term survival analysis of the randomized phase III E3805 chaarted trial. J ClinOncol2018 ; 36 : 1080–7. 10.1200/JCO.2017.75.3657.Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer : long-term survival analysis of the randomized phase III E3805 chaarted trial. J ClinOncol2018 ; 36 : 1080–7. 10.1200/JCO.2017.75.3657.Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- And high-burden metastatic hormone sensitive prostate cancer : Long-term survival results from the STAMPEDE trial. AnnOncol2019 ; 30 : 1992–2003. 10.1093/annonc/mdz396.Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- And high-burden metastatic hormone sensitive prostate cancer : Long-term survival results from the STAMPEDE trial. AnnOncol2019 ; 30 : 1992–2003. 10.1093/annonc/mdz396.Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med2017 ; 377 : 352–60. 10.1056/NEJMoa1704174.Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med2017 ; 377 : 352–60. 10.1056/NEJMoa1704174.James ND, de Bono JS, Spears MR, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med2017 ; 377 : 338–51. 10.1056/NEJMoa1702900.James ND, de Bono JS, Spears MR, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med2017 ; 377 : 338–51. 10.1056/NEJMoa1702900.Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med2019 ; 381 : 121–31. 10.1056/NEJMoa1903835.Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med2019 ; 381 : 121–31. 10.1056/NEJMoa1903835.Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. Arches : A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J ClinOncol2019 ; 37 : 2974–86. 10.1200/JCO.19.00799.Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. Arches : A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J ClinOncol2019 ; 37 : 2974–86. 10.1200/JCO.19.00799.Taneja SS. Re : Apalutamide for metastatic, castration-sensitive prostate cancer. J Urol2019 ; 202 : 661. 10.1097/01.JU.0000577260.12278.1c.Taneja SS. Re : Apalutamide for metastatic, castration-sensitive prostate cancer. J Urol2019 ; 202 : 661. 10.1097/01.JU.0000577260.12278.1c.J Clin Oncol 40, 2022 (suppl 17 ; abstr LBA5004.J Clin Oncol 40, 2022 (suppl 17 ; abstr LBA5004.Motzer RJ, Russo P. Cytoreductive Nephrectomy — Patient Selection Is Key. N Engl J Med2018 ; 379 : 481–2. 10.1056/NEJMe1806331.Motzer RJ, Russo P. Cytoreductive Nephrectomy — Patient Selection Is Key. N Engl J Med2018 ; 379 : 481–2. 10.1056/NEJMe1806331.Hartford AC, Gohongi T, Fukumura D, et al. Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site : Potential role of host-tumor interaction. CancerRes2000 ; 60 : 2128–31.Hartford AC, Gohongi T, Fukumura D, et al. Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site : Potential role of host-tumor interaction. CancerRes2000 ; 60 : 2128–31.Psaila B, Lyden D. The metastatic niche : Adapting the foreign soil. Nat. Rev. Cancer 2009 ; 9 : 285–93. 10.1038/nrc2621.Psaila B, Lyden D. The metastatic niche : Adapting the foreign soil. Nat. Rev. Cancer 2009 ; 9 : 285–93. 10.1038/nrc2621.Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J ClinOncol2016 ; 34 : 2835–42. 10.1200/JCO.2016.67.4788.Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J ClinOncol2016 ; 34 : 2835–42. 10.1200/JCO.2016.67.4788.Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. EurUrol 2014 ; 65 : 1058–66. 10.1016/j.eururo.2013.11.012.Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. EurUrol 2014 ; 65 : 1058–66. 10.1016/j.eururo.2013.11.012.Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer : Data from the munich cancer registry. EurUrol 2014 ; 66 : 602–3. 10.1016/j.eururo.2014.04.009.Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer : Data from the munich cancer registry. EurUrol 2014 ; 66 : 602–3. 10.1016/j.eururo.2014.04.009.Sooriakumaran P, Nyberg T, Akre O, et al. Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy. EurUrol2017 ; 72 : 345–51. 10.1016/j.eururo.2017.04.002.Sooriakumaran P, Nyberg T, Akre O, et al. Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy. EurUrol2017 ; 72 : 345–51. 10.1016/j.eururo.2017.04.002.Boevé LMS, Hulshof MCCM, Vis AN, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Tria. EurUrol2019 ; 75 : 410–8. 10.1016/j.eururo.2018.09.008.Boevé LMS, Hulshof MCCM, Vis AN, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Tria. EurUrol2019 ; 75 : 410–8. 10.1016/j.eururo.2018.09.008.Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE) : a randomised controlled phase 3 trial. Lancet 2018 ; 392 : 2353–66. 10.1016/S0140–6736(18) 32486–3.Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE) : a randomised controlled phase 3 trial. Lancet 2018 ; 392 : 2353–66. 10.1016/S0140–6736(18) 32486–3.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer Version 1.2023 — September 16, 2022 https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer Version 1.2023 — September 16, 2022 https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.Burdett S, Boevé LM, Ingleby FC, et al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer : A STOPCAP Systematic Review and Meta-analysis. EurUrol2019 ; 76 : 115–24. 10.1016/j.eururo.2019.02.003.Burdett S, Boevé LM, Ingleby FC, et al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer : A STOPCAP Systematic Review and Meta-analysis. EurUrol2019 ; 76 : 115–24. 10.1016/j.eururo.2019.02.003.Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. EurUrol 2014 ; 65 : 1058–66. 10.1016/j.eururo.2013.11.012.Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. EurUrol 2014 ; 65 : 1058–66. 10.1016/j.eururo.2013.11.012.Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer : Data from the munich cancer registry. EurUrol 2014 ; 66 : 602–3. 10.1016/j.eururo.2014.04.009.Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer : Data from the munich cancer registry. EurUrol 2014 ; 66 : 602–3. 10.1016/j.eururo.2014.04.009.Sooriakumaran P, Nyberg T, Akre O, et al. Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy. EurUrol 2017 ; 72 : 345–51. 10.1016/j.eururo.2017.04.002.Sooriakumaran P, Nyberg T, Akre O, et al. Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy. EurUrol 2017 ; 72 : 345–51. 10.1016/j.eururo.2017.04.002.Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases : Results of a feasibility and case-control study. J Urol 2015 ; 193 : 832–8. 10.1016/j.juro.2014.09.089.Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases : Results of a feasibility and case-control study. J Urol 2015 ; 193 : 832–8. 10.1016/j.juro.2014.09.089.Heidenreich A, Fossati N, Pfister D, et al. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. EurUrolOncol 2018 ; 1 : 46–53. 10.1016/j.euo.2018.03.002.Heidenreich A, Fossati N, Pfister D, et al. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. EurUrolOncol 2018 ; 1 : 46–53. 10.1016/j.euo.2018.03.002.Jang WS, Kim MS, Jeong WS, et al. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases?BJU Int2018 ; 121 : 225–31. 10.1111/bju.13992.Jang WS, Kim MS, Jeong WS, et al. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases?BJU Int2018 ; 121 : 225–31. 10.1111/bju.13992.Gundem G, Van Loo P, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015 ; 520 : 353–7. 10.1038/nature14347.Gundem G, Van Loo P, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015 ; 520 : 353–7. 10.1038/nature14347.Prostate cancer. EAUguidelines.Prostate cancer. EAUguidelines.Paul Rogowski, Radiat Oncol. 2021 ; 16 : 125. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247211/.Paul Rogowski, Radiat Oncol. 2021 ; 16 : 125. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247211/.Phillips R, Shi WY, Deek M, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer : The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol2020 ; 6 : 650–9. 10.1001/jamaoncol.2020.0147.Phillips R, Shi WY, Deek M, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer : The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol2020 ; 6 : 650–9. 10.1001/jamaoncol.2020.0147.Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence : A prospective, randomized, multicenter phase II trial. J ClinOncol 2018 ; 36 : 446–53. 10.1200/JCO.2017.75.4853.Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence : A prospective, randomized, multicenter phase II trial. J ClinOncol 2018 ; 36 : 446–53. 10.1200/JCO.2017.75.4853.Ploussard, G., et al. Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer : A Systematic Review. EurUrol, 2019. 76 : 493.Ploussard, G., et al. Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer : A Systematic Review. EurUrol, 2019. 76 : 493.Porres D, Pfister D, Thissen A, et al. The role of salvage extended lymph node dissection in patients with rising PSA and PET / CT scan detected nodal recurrence of prostate cancer. Prostate Cancer Prostatic Dis 2017 ; 20 : 85–92. 10.1038/pcan.2016.54.Porres D, Pfister D, Thissen A, et al. The role of salvage extended lymph node dissection in patients with rising PSA and PET / CT scan detected nodal recurrence of prostate cancer. Prostate Cancer Prostatic Dis 2017 ; 20 : 85–92. 10.1038/pcan.2016.54.Fossati N, Suardi N, Gandaglia G, et al. Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer : Results from a Large, Multi-institutional Analysis. EurUrol 2019 ; 75 : 176–83. 10.1016/j.eururo.2018.09.009Fossati N, Suardi N, Gandaglia G, et al. Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer : Results from a Large, Multi-institutional Analysis. EurUrol 2019 ; 75 : 176–83. 10.1016/j.eururo.2018.09.009

The authors declare that there are no conflicts of interest present.